Related references
Note: Only part of the references are listed.The orphan receptor GPR55 is a novel cannabinoid receptor
E. Ryberg et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Acute effects of Δ9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity
Georg Juckel et al.
SCHIZOPHRENIA RESEARCH (2007)
Cannabinoid receptor antagonists counteract sensorimotor Gating deficits in the phencyclidine model of psychosis
Martina Ballmaier et al.
NEUROPSYCHOPHARMACOLOGY (2007)
The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval
Franz X. Vollenweider et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies
Belen Ferrer et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
The acute effects of cannabinoids on memory in humans: a review
Mohini Ranganathan et al.
PSYCHOPHARMACOLOGY (2006)
Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels
Franz X. Vollenweider et al.
BIOLOGICAL PSYCHIATRY (2006)
Cannabidiol monotherapy for treatment-resistant schizophrenia
Antonio Waldo Zuardi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2006)
Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice
LE Long et al.
NEUROPSYCHOPHARMACOLOGY (2006)
The effect of Δ9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats
DT Malone et al.
BEHAVIOURAL BRAIN RESEARCH (2006)
Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Δ9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract
T Nadulski et al.
THERAPEUTIC DRUG MONITORING (2005)
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
JP Despres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Agonistic properties of cannabidiol at 5-HT1a receptors
EB Russo et al.
NEUROCHEMICAL RESEARCH (2005)
Mismatch negativity in schizophrenia: a meta-analysis
D Umbricht et al.
SCHIZOPHRENIA RESEARCH (2005)
Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics
H Lublin et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2005)
Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice
FA Moreira et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Activation of D1, but not D2 receptors potentiates dizocilpine-mediated disruption of prepulse inhibition of the startle
M Bortolato et al.
NEUROPSYCHOPHARMACOLOGY (2005)
Neurochemical analysis of rat strain differences in the startle gating-disruptive effects of dopamine agonists
NR Swerdlow et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2005)
The effect of SR 141716 and apomorphine on sensorimotor gating in Swiss mice
DT Malone et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2004)
Cannabis use and psychotic disorders: an update
W Hall et al.
DRUG AND ALCOHOL REVIEW (2004)
Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum
VMC Guimaraes et al.
LIFE SCIENCES (2004)
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and Schizoaffective disorder
HY Meltzer et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms
A Giuffrida et al.
NEUROPSYCHOPHARMACOLOGY (2004)
Cannabis-associated psychosis - Current status of research
FM Leweke et al.
CNS DRUGS (2004)
Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia
K Ludewig et al.
BIOLOGICAL PSYCHIATRY (2003)
Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats
CD Verrico et al.
SYNAPSE (2003)
Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse
SC Azad et al.
LEARNING & MEMORY (2003)
Cannabinoid-induced Fos expression within A10 doparninergic neurons
S Patel et al.
BRAIN RESEARCH (2003)
Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat
RS Martin et al.
PSYCHOPHARMACOLOGY (2003)
Cannabidiol: An overview of some pharmacological aspects
R Mechoulam et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain
S Mato et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice
K Monory et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Reduced binocular depth inversion in schizophrenic patients
U Schneider et al.
SCHIZOPHRENIA RESEARCH (2002)
Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers
D Umbricht et al.
BIOLOGICAL PSYCHIATRY (2002)
Dopamine D2 receptors and their role in atypical antipsychotic action:: Still necessary and may even be sufficient
S Kapur et al.
BIOLOGICAL PSYCHIATRY (2001)
A systems model of altered consciousness: Integrating natural and drug-induced psychoses
FX Vollenweider et al.
BRAIN RESEARCH BULLETIN (2001)
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
T Bisogno et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies
DL Braff et al.
PSYCHOPHARMACOLOGY (2001)
Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation
M Pistis et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2001)
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review
MA Geyer et al.
PSYCHOPHARMACOLOGY (2001)
Diagnosing schizophrenia in the initial prodromal phase
J Klosterkötter et al.
ARCHIVES OF GENERAL PSYCHIATRY (2001)
Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus
N Hajos et al.
NEUROSCIENCE (2001)
Studies on [H-3]CP-55940 binding in the human central nervous system: Regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use
B Dean et al.
NEUROSCIENCE (2001)
Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia
S Kapur et al.
ANNUAL REVIEW OF MEDICINE (2001)
Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers -: Implications for models of cognitive deficits in schizophrenia
D Umbricht et al.
ARCHIVES OF GENERAL PSYCHIATRY (2000)
Pharmacological and molecular targets in the search for novel antipsychotics
B Scatton et al.
BEHAVIOURAL PHARMACOLOGY (2000)
Different effects of nabilone and cannabidiol on binocular depth inversion in man
FM Leweke et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2000)
To model a psychiatric disorder in animals: Schizophrenia as a reality test
BK Lipska et al.
NEUROPSYCHOPHARMACOLOGY (2000)